저작자표시 - 비영리 - 동일조건변경허락 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비

Size: px

Start display at page:

Download "저작자표시 - 비영리 - 동일조건변경허락 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비"

경환 함
5 years ago
Views:

1 저작자표시 - 비영리 - 동일조건변경허락 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 동일조건변경허락. 귀하가이저작물을개작, 변형또는가공했을경우에는, 이저작물과동일한이용허락조건하에서만배포할수있습니다. 귀하는, 이저작물의재이용이나배포의경우, 이저작물에적용된이용허락조건을명확하게나타내어야합니다. 저작권자로부터별도의허가를받으면이러한조건들은적용되지않습니다. 저작권법에따른이용자의권리는위의내용에의하여영향을받지않습니다. 이것은이용허락규약 (Legal Code) 을이해하기쉽게요약한것입니다. Disclaimer

33 β

39 exp Ÿ

42 * Source : MOHW & KCDC, KNHANES

43 * Source : KCDC, Center for Genome Science, 2006.

44 * Source : KCDC, Center for Genome Science, 2006.

45 * Source : Chun KH et al., 2007 * Source : KCDC, 2007

52 * GFR, Glomerular filtration rate ** Source : Kim YS & Lim CS, 2008

56 * CIDP, Chronic Inflammatory Demyelinating Polyneuropathy ** Source : Boulton et al., 2005; Diabetes, 2011

57 * Source : Diabetes, 2011

66 * QALY, Quality Adjusted life year; DFLE, Diability free life expectancy; IFLE, Impairmalet free life expectancy; HFLE, Handicap free life expectancy; DALY, Disability adjusted life year ** Source : Sin YS et al., 2004.

67 * DALY, Disability-adjusted life year; YLL, Years of life lost; YLD, Years lost to disability

72 * CHD, Coronory heart disease ** Source : CDC, 1996; Eastman et al., 1997b; Hoerger et al., 2004; Zhou et al., 2005

74 * ESRD, End-stage renal disease

75 * LEA, Lower-extremity amputation

76 * SMI, Unrecognized silent myocardial ischemia; CA/MI, Cardiac arrest or myocardial infarction

80 * Source : Statistics Korea, 2010

82 * SBP, Systolic blood pressure; DBP, Diastolic blood pressure * Source : KNHANES, 1998 * SBP, Systolic blood pressure; DBP, Diastolic blood pressure * Source : KNHANES, 2010

83 * TC, total cholesterol; HDL-C, High Density lipoprotein cholesterol ** Source : KNHANES, 1998

84 * TC, total cholesterol; HDL-C, High Density lipoprotein cholesterol ** Source : KNHANES, 2010

85 * Source : KNHANES, 1998; KNHANES, 2010

88 Ln

90 Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr

91 Pr

92 * Source : KNHANES, 2010 Pr Pr Pr Pr

93 Pr Pr

94 Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr

95 Pr Pr Pr Pr Pr * NPDR, Nonproliferative retinopathy; PDR, Proliferative retinopathy, ME, Significant macular edema

96 * LEA, Lower extremity amputation

97 * Source : Eastman et al., 1997b; Hoerger et al., 2004

100

101

102

103

104 * ESRD, End stage renal disease * Source : Alder et al., 2003

105

106

107

108

109 * MR, mortality rate; HR, hazard rate; TP, transitional probability ** Source : Dong, Orians, Manninen. 1997; Hoerger et al., 2004

110

111 * ESRD, End-stage renal disease

112

113 * SMI, Unrecognized silent myocardial ischemia; CA, Cardiac arrest; MI, myocardial infarction

114 * SMI, Unrecognized silent myocardial ischemia; CA, Cardiac arrest; CHD, coronary heart disease; MI, myocardial infarction ** Source : Hoerger TJ, et al., 2004

115 * Source : Eastman et al., 1997a; Hoerger et al., 2004a; Zhou et al., 2005

116

117 exp

118 * CA, Cardiac arrest; CHD, coronary heart disease; MI, myocardial infarction ** Source : Hunink et al., 1997 ; Hoerger et al., 2004

119 * Source : Weinstein et al. (1987); Hoerger et al. (2004)

120 * CA, Cardiac arrest; MI, myocardial infarction ** Source : Hunink et al. (1997); Hoerger et al. (2004)

121 * CA, Cardiac arrest; MI, myocardial infarction ** Source : Weinstein et al. (1987); Hoerger et al. (2004)

122 * CA, Cardiac arrest; MI, myocardial infarction ** Source : Hunink et al. (1987); Hoerger et al. (2004)

123

124 * CA, Cardiac arrest; MI, myocardial infarction

125 21 * CA, Cardiac arrest; MI, myocardial infarction

126 * CA, Cardiac arrest; MI, myocardial infarction 22 * CA, Cardiac arrest; MI, myocardial infarction

127

128

129 * SMI, Unrecognized silent myocardial ischemia; CA, Cardiac arrest; MI, myocardial infarction

130

131 * Source : Hoerger et al., 2004 exp

132

133

134

135

136

137

138

139

140

141 * Source : Murray & Lopez. The global burden of disease. Harvard University Press

142

143

144 * NPDR, nonproliferative retinopathy; PDR, roliferative retinopathy; ME, significant macular edema

145 * NPDR, nonproliferative retinopathy; PDR, roliferative retinopathy; ME, significant macular edema * NPDR, nonproliferative retinopathy; PDR, roliferative retinopathy; ME, significant macular edema

146 * NPDR, nonproliferative retinopathy; PDR, roliferative retinopathy; ME, significant macular edema

147 * MA, microalbuminuria; ESRD, end-stage renal disease * MA, microalbuminuria; ESRD, end-stage renal disease

148 * MA, microalbuminuria; ESRD, end-stage renal disease * MA, microalbuminuria; ESRD, end-stage renal disease

149 * SN, symptomatic neuropathy; LEA, lower-extremity amputation

150 * SN, symptomatic neuropathy; LEA, lower-extremity amputation * SN, symptomatic neuropathy

151 * SN, symptomatic neuropathy; LEA, lower-extremity amputation

152 * SMI, unrecognized silent myocardial ischemia; CA/MI, cadiac arrest/mycardial infarction * SMI, unrecognized silent myocardial ischemia; CA/MI, cadiac arrest/mycardial infarction

153 * SMI, unrecognized silent myocardial ischemia; CA/MI, cadiac arrest/mycardial infarction * SMI, unrecognized silent myocardial ischemia; CA/MI, cadiac arrest/mycardial infarction

154

155

156

157 * YLL, year of life lost

158 * YLD, years lived with disability

159

160 * YLL, year of life lost; YLD, years lived with disability; DALY, disability adjusted life year

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,